- Home
- OPHC vs ATYR Comparison
OPHC vs ATYR Comparison
Compare OPHC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | ATYR |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 69.2M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | OPHC | ATYR |
|---|---|---|
| Price | $5.44 | $0.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 32.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,115.63 | N/A |
| Revenue Next Year | N/A | $18,728.62 |
| P/E Ratio | $7.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $0.64 |
| 52 Week High | $5.59 | $7.29 |
Technical Indicators
Market Signals| Indicator | OPHC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 68.14 | 55.97 |
| Support Level | $4.00 | $0.67 |
| Resistance Level | $5.59 | $1.09 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 65.63 | 47.73 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.